1. FisherFS, BultmanMW, JohnsonSM, PappagianisD, ZaborskyE (2007) Coccidioides niches and habitat parameters in the southwestern United States: a matter of scale. Ann N Y Acad Sci 1111: 47–72.
2. BlundellGP, CastleberryMW, LoweEP, ConverseJL (1961) The pathology of Coccidioides immitis in the Macaca mulatta. Am J Pathol 39: 613–630.
3. WiseHZ, HungCY, WhistonE, TaylorJW, ColeGT (2013) Extracellular ammonia at sites of pulmonary infection with Coccidioides posadasii contributes to severity of the respiratory disease. Microb Pathog 59–60: 19–28.
4. Anonymous (2013) Increase in reported coccidioidomycosis - United States, 1998–2011. Morb Mortal Wkly Rep 62: 217–221.
5. Marsden-HaugN, GoldoftM, RalstonC, LimayeAP, ChuaJ, et al. (2013) Coccidioidomycosis acquired in Washington State. Clin Infect Dis 56: 847–850.
6. RuddyBE, MayerAP, KOMG, LabonteHR, BorovanskyJA, et al. (2011) Coccidioidomycosis in African Americans. Mayo Clin Proc 86: 63–69.
7. ColeGT, HurtgenBJ, HungC-Y (2012) Progress toward a human vaccine against coccidioidomycosis. Curr Fungal Infect Rep 6: 235–244.
8. PappagianisD (1993) Evaluation of the protective efficacy of the killed Coccidioides immitis spherule vaccine in humans. The Valley Fever Study Group. Am Rev Respir Dis 148: 656–660.
9. XueJ, ChenX, SelbyD, Hung-Y, YuJ-J, ColeGT (2009) A genetically engineered live attenuated vaccine of Coccidioides posadasii protects BALB/c mice against coccidioidomycosis. Infect Immun 77: 3196–3208.
10. BalamayooranT, BatraS, BalamayooranG, CaiS, KobayashiKS, et al. (2011) Receptor-interacting protein 2 controls pulmonary host defense to Escherichia coli infection via the regulation of interleukin-17A. Infect Immun 79: 4588–4599.
11. HungC-Y, GonzalezA, WüthrichM, KleinBS, ColeGT (2011) Vaccine immunity to coccidioidomycosis occurs by early activation of three signal pathways of T helper cell response (Th1, Th2, and Th17). Infect Immun 79: 4511–4522.
12. HungC-Y, HurtgenBJ, BellecourtM, SandersonSD, MorganEL, et al. (2012) An agonist of human complement fragment C5a enhances vaccine immunity against Coccidioides infection. Vaccine 30: 4681–4690.
13. MorganEL, MorganBN, SteinEA, VitrsEL, ThomanML, et al. (2009) Enhancement of in vivo and in vitro immune functions by a conformationally biased, response-selective agonist of human C5a: implications for a novel adjuvant in vaccine design. Vaccine 28: 463–469.
14. PhillipsJA, MorganEL, DongY, ColeGT, McMahanC, et al. (2009) Single-step conjugation of bioactive peptides to proteins via a self-contained succinimidyl bis-arylhydrazone. Bioconjug Chem 20: 1950–1957.
15. FiererJ, WatersC, WallsL (2006) Both CD4+ and CD8+ T cells can mediate vaccine-induced protection against Coccidioides immitis infection in mice. J Infect Dis 193: 1323–1331.
16. NanjappaSG, HeningerE, WüthrichM, GasperDJ, KleinBS (2012) Tc17 cells mediate vaccine immunity against lethal fungal pneumonia in immune deficient hosts lacking CD4+ T cells. PLoS Pathog 8: e1002771 doi:10.1371/journal.ppat.1002771
17. HurtgenBJ, HungC-Y, OstroffGR, LevitzSM, ColeGT (2012) Construction and evaluation of a novel recombinant T cell epitope-based vaccine against coccidioidomycosis. Infect Immun 80: 3960–3974.
18. RosaDS, RibeiroSP, Cunha-NetoE (2010) CD4+ T cell epitope discovery and rational vaccine design. Arch Immunol Ther Exp (Warsz) 58: 121–130.
19. HuangH, OstroffGR, LeeCK, SpechtCA, LevitzSM (2010) Robust stimulation of humoral and cellular immune responses following vaccination with antigen-loaded β-glucan particles. MBio 1: e00164–10.
20. IkeuchiN, FutamiJ, HosoiA, NojiS, KurachiM, et al. (2010) Efficient cross-presentation of soluble exogenous antigens introduced into dendritic cells using a weak-based amphiphilic peptide. Biochem Biophys Res Commun 392: 217–222.
21. TeszGJ, AouadiM, ProtM, NicoloroSM, BoutetE, et al. (2011) Glucan particles for selective delivery of siRNA to phagocytic cells in mice. Biochem J 436: 351–362.
22. TamerisMD, HatherillM, LandryBS, ScribaTJ, SnowdenMA, et al. (2013) Safety and efficacy of MVA85A, a new tuberculosis vaccine in infants previously vaccinated with BCG: a randomized, placebo-controlled phase 2b trial. Lancet 381: 1021–1028.
23. RappuoliR, MandlCW, BlackS, De GregorioE (2011) Vaccines for the twenty-first century society. Nat Rev Immunol 11: 865–872.
24. MorganEL, ThomanML, SandersonSD, PhillipsJA (2010) A novel adjuvant for vaccine development in the aged. Vaccine 28: 8275–8279.
25. LivingstonB, CrimiC, NewmanM, HigashimotoY, AppellaE, et al. (2002) A rational strategy to design multiepitope immunogens based on multiple Th lymphocyte epitopes. J Immunol 168: 5499–5506.
26. YanoA, OnozukaA, Asahi-OzakiY, ImaiS, HanadaN, et al. (2005) An ingenious design for peptide vaccines. Vaccine 23: 2322–2326.